By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The Ontario Genomics Institute has invested C$100,000 (US$101,000) in Toronto-based molecular diagnostics developer Rna Diagnostics to support further development of the company's lead test for chemotherapy management.

OGI provided the funding to Rna Diagnostics, which has its research lab in Sudbury, Ontario and uses technology developed at Sudbury's Laurentian University, through its Pre-Commercialization Business Development Fund.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.

Differences in DNA methylation could be used to distinguish between DNA samples obtained from identical twins, researchers say.

A retrovirus that's been integrated into the human genome appears to have a role in embryonic development, researchers report.

A report from MIT identifies areas of scientific research where declining research support is hindering needed advances.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.